Gilenya fails to win NICE backing in draft guidance

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya fails to win NICE backing in draft guidance

Postby MSUK » Thu Dec 01, 2011 12:54 am

Image

The UK's health cost body National Institute for Health and Clinical Excellence, or NICE, in its revised draft guidance did not recommend Swiss pharmaceutical giant Novartis' multiple sclerosis pill Gilenya, as it believes the drug would not be cost effective for the National Health Service, or NHS, in comparison with other available treatments. NICE has not yet issued guidance for the NHS.

Gilenya, or fingolimod, is a daily capsule that could reduce relapses in some people who have a particular type of multiple sclerosis.

Even after a proposed discount from Novartis, NICE's independent appraisal committee is not convinced that offering the drug would be a cost effective option for the NHS, when compared with existing treatments such as beta interferons.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2211
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service